Literature DB >> 28327099

Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status.

Héctor Rodríguez-Angulo1, Juan Marques2, Ivan Mendoza2, Marco Villegas3, Alfredo Mijares4, Núria Gironès5, Manuel Fresno5.   

Abstract

BACKGROUND: Chagas disease is caused by the protozoan Trypanosoma cruzi and is characterized by heart failure and sudden death. Identifying which factors are involved in evolution and treatment response is actually challenging. Thus, the aim of this work was to determine the Th1/Th17 (IL-6, IL-2, TNF, IL-17 and IFN-γ) and Th2 (IL-4 and IL-10) serum profile in Venezuelan Chagasic patients stratified according amiodarone treatment, hypertension and arrhythmias.
METHODS: Sera from 38 chagasic patients were analyzed to determine the level of cytokines by Multiplexed Bead-Based Immunoassays. ANOVA test was applied to determine differences for each group. Additionally, a Linear Discriminant Analysis (LDA) was applied to observe the accuracy of different cytokines to discriminate between the groups.
RESULTS: The levels of several cytokines were significantly higher in the high-risk of sudden death and untreated group. LDA showed that IL-2, IFN-γ and IL-10 were the best cytokines for discriminating between high-risk of sudden death and untreated patients versus low-risk of sudden death, treated and control groups.
CONCLUSIONS: High IL-2 levels seem to identify patients with high-risk of sudden death and seems adequate as treatment efficacy marker. To our knowledge, this is the first report about the anti-inflammatory role of the amiodarone in Chagas disease, suggesting an inmunomodulatory effect that may be exploited as coadjutant therapy in chronic Chagas disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28327099      PMCID: PMC5361844          DOI: 10.1186/s12879-017-2324-x

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  39 in total

1.  Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro.

Authors:  Daniel Adesse; Eduardo Meirelles Azzam; Maria de Nazareth L Meirelles; Julio A Urbina; Luciana R Garzoni
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 2.  The TGF-β pathway as an emerging target for Chagas disease therapy.

Authors:  T C Araújo-Jorge; M C Waghabi; S Bailly; J-J Feige
Journal:  Clin Pharmacol Ther       Date:  2012-09-19       Impact factor: 6.875

3.  Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.

Authors:  Simone Garcia; Carolina O Ramos; Juliana F V Senra; Fabio Vilas-Boas; Maurício M Rodrigues; Antonio C Campos-de-Carvalho; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile.

Authors:  Gustavo Benaim; Vanessa Hernandez-Rodriguez; Sheira Mujica-Gonzalez; Lourdes Plaza-Rojas; May Li Silva; Nereida Parra-Gimenez; Yael Garcia-Marchan; Alberto Paniz-Mondolfi; Graciela Uzcanga
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

5.  Captopril ameliorates myocarditis in acute experimental Chagas disease.

Authors:  Juan S Leon; Kegiang Wang; David M Engman
Journal:  Circulation       Date:  2003-04-21       Impact factor: 29.690

6.  Interleukin-2 as a predictor of early postoperative atrial fibrillation after cardiopulmonary bypass graft (CABG).

Authors:  Łukasz Hak; Jolanta Myśliwska; Joanna Wieckiewicz; Krzysztof Szyndler; Janusz Siebert; Jan Rogowski
Journal:  J Interferon Cytokine Res       Date:  2009-06       Impact factor: 2.607

Review 7.  Interleukin-17.

Authors:  F Fossiez; J Banchereau; R Murray; C Van Kooten; P Garrone; S Lebecque
Journal:  Int Rev Immunol       Date:  1998       Impact factor: 5.311

8.  Bed bugs (Cimex lectularius) as vectors of Trypanosoma cruzi.

Authors:  Renzo Salazar; Ricardo Castillo-Neyra; Aaron W Tustin; Katty Borrini-Mayorí; César Náquira; Michael Z Levy
Journal:  Am J Trop Med Hyg       Date:  2014-11-17       Impact factor: 2.345

9.  Economic crisis and increased immigrant mobility: new challenges in managing Chagas disease in Europe.

Authors:  Yves Jackson; Monica Varcher Herrera; Joaquim Gascon
Journal:  Bull World Health Organ       Date:  2014-09-09       Impact factor: 9.408

10.  Analysis of the dynamics of infiltrating CD4(+) T cell subsets in the heart during experimental Trypanosoma cruzi infection.

Authors:  Cristina Sanoja; Sofía Carbajosa; Manuel Fresno; Núria Gironès
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more
  7 in total

Review 1.  Pathology and Pathogenesis of Chagas Heart Disease.

Authors:  Kevin M Bonney; Daniel J Luthringer; Stacey A Kim; Nisha J Garg; David M Engman
Journal:  Annu Rev Pathol       Date:  2018-10-24       Impact factor: 23.472

2.  Chagas disease: modulation of the inflammatory response by acetylcholinesterase in hematological cells and brain tissue.

Authors:  Aniélen D Silva; Nathieli B Bottari; Guilherme M do Carmo; Matheus D Baldissera; Carine F Souza; Vanessa S Machado; Vera M Morsch; Maria Rosa C Schetinger; Ricardo E Mendes; Silvia G Monteiro; Aleksandro S Da Silva
Journal:  Mol Cell Biochem       Date:  2017-08-01       Impact factor: 3.396

Review 3.  The Unsolved Jigsaw Puzzle of the Immune Response in Chagas Disease.

Authors:  Gonzalo R Acevedo; Magalí C Girard; Karina A Gómez
Journal:  Front Immunol       Date:  2018-08-24       Impact factor: 7.561

4.  Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection.

Authors:  Juliana Magalhães Chaves Barbosa; Yasmin Pedra Rezende; Tatiana Galvão de Melo; Gabriel de Oliveira; Cynthia Machado Cascabulho; Evelyn Nunes Goulart da Silva Pereira; Anissa Daliry; Kelly Salomão Salem
Journal:  Microbiol Spectr       Date:  2022-02-09

5.  Trypanosoma cruzi activates mouse cardiac fibroblasts in vitro leading to fibroblast-myofibroblast transition and increase in expression of extracellular matrix proteins.

Authors:  Laura Lacerda Coelho; Isabela Resende Pereira; Mirian Claudia de Souza Pereira; Liliane Mesquita; Joseli Lannes-Vieira; Daniel Adesse; Luciana Ribeiro Garzoni
Journal:  Parasit Vectors       Date:  2018-01-30       Impact factor: 3.876

Review 6.  Translating Chagasic dilating cardiomyopathy to surgical therapies: An under published global challenge.

Authors:  Zoe C Groom; Vasileios Zochios; Aristotle D Protopapas
Journal:  SAGE Open Med       Date:  2019-12-18

7.  Interleukin-9 in Immunopathology of Trypanosoma cruzi Experimental Infection.

Authors:  Nadjania Saraiva de Lira Silva; Cristina Mary Orikaza; Fabiana Rodrigues de Santana; Luana Aguiar Dos Santos; Bruno Ramos Salu; Maria Luiza Vilela Oliva; Rita de Cássia Sinigaglia; Renato Arruda Mortara
Journal:  Front Cell Infect Microbiol       Date:  2021-10-15       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.